|
|
 |
|
Viewing report
|
|
|
|
Cytokines, Chemokines, and Growth Factors- Key Targets for Immunotherapeutic Development
Drug and Market Development Publishing, Nov 2003, Pages: 1,200
The cytokines, chemokines, and growth factors market has $90 billion revenue potential.
Cytokine-based research is revolutionizing the treatment of inflammatory, infectious, and neoplastic diseases.
Many of the original cytokine treatments (i.e. interferon-1beta, and Tnf-alpha) have given way to more refined approaches as the knowledge and discovery process concerning complex cytokine and chemokine networks becomes further clarified.
The increased market penetration of approved drugs targeting cytokines and their receptors has spurred several pharmaceutical companies to devote a portion of their pipelines to the development of these immunotherapeutics.
The Cytokines, Chemokines, and Growth Factors Market Analysis Report provides a thorough review of this promising drug target class.
This Report will help you:
- Pinpoint the full market potential of cytokine- and chemokine-based drugs with an examination of the projected market impact through 2009.
- Identify commercial opportunities for immunotherapeutic drug technologies via a thorough assessment of current and emerging drug development platforms, including particular immunodiagnostics utilized to discover novel cytokine drugs.
- Discover what's new in the industry with a comprehensive update and discussion of novel cytokine, chemokine and growth factor classification and nomenclature schemes.
- Obtain a complete and extensive appraisal of the development status for all cytokine-based drugs and clinical trials of all phases, including pre-clinical studies, via a meta-analysis of each disease application and investigated cytokine.
- Get an up-to-date review of pathogenic cytokine findings through an evaluation of the latest developments critical to novel cytokine-based products and clinical trials, including a prodigious list of references and key Web site links.
- Identify trends in each of the immunotherapeutic sub-sectors with an in-depth review of monoclonals, receptor antagonists, small molecule growth factors, signal cascades, ex vivo cell transfer, and gene therapy
- Learn about the current patent and licensing landscape of immunotherapeutics from a critical evaluation of patent issues, licensing agreements, and partnerships of immunotherapeutic companies, including associated marketing profiles of major immunotherapeutic/biologicals companies.
- Look inside 70 companies utilizing cytokines and chemokines for drug development, including their product pipelines, financial standing, partnerships and alliances, and more.
This Report will benefit the following professionals involved in immunotherapeutics, biologics, and immunodiagnostics:
- Presidents, Vice Presidents, Marketing Directors, Clinical Trial Directors, Research Managers, Senior Scientists, and other major decision-makers.
Customers who bought this item also bought
Current Drug Development Market for Cytokines, Chemokines and Growth Factors
Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies
Structure-Guided Drug Design: Rediscovering the Importance of Drug Structure for Drug Discovery
Drug Delivery in Cancer - Technologies, Markets and Companies
Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates
Cytokine Therapeutics: Current and Future Markets in Inflammatory Disease
Laboratory Chemical Reagents - Global Strategic Business Report
Growth Factors ( Blood And Tissue ) - Global Strategic Business Report
|
|
|
|
